Dashboard Tools Market News Investing Ideas Pricing
Search 100,000+ stocks...
English EN
Deutsch DE Español ES
Sign Up
Log in
L

Life Science REIT PLC
LSE:LABS

Watchlist Manager
Life Science REIT PLC
LSE:LABS
Watchlist
Price: 43.1 GBX
Market Cap: £150.9m
Write Note Create Alert Ask AI

Wall St Price Targets

LABS Price Targets Summary
Life Science REIT PLC

There are no price targets for LABS.
LABS Lowest Forecast
Wall Street Target
Not Available
LABS Average Forecast
Wall Street Target
Not Available
LABS Highest Forecast
Wall Street Target
Not Available
Lowest Forecast
Price Target
Not Available
Average Forecast
Price Target
Not Available
Highest Forecast
Price Target
Not Available
Life Science REIT PLC Competitors:
Price Targets
HLIO
Helios Technologies Inc
10% Upside
WELL
Welltower Inc
14% Upside
UHT
Universal Health Realty Income Trust
6% Upside
M
MAC
MacroAsia Corp
90% Upside
HLIO
Helios Technologies Inc
10% Upside
WELL
Welltower Inc
14% Upside
UHT
Universal Health Realty Income Trust
6% Upside
M
MAC
MacroAsia Corp
90% Upside
LTC
LTC Properties Inc
10% Upside
EFX
Equifax Inc
21% Upside
UE
Urban Edge Properties
11% Upside

Revenue
Forecast

14% / Year
Past Growth
19% / Year
Estimated Growth
Estimates Accuracy
13%
Average Beat
14% / Year
Past Growth
19% / Year
Estimated Growth
Estimates Accuracy
13%
Average Beat

Over the last 2 years, the compound annual growth rate for Revenue has been 14%. The projected CAGR for the next 2 years is 19%.

What are analyst estimates?

Gross Profit
Forecast

15% / Year
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
15% / Year
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
Gross Profit Forecast
is not available for Life Science REIT PLC

Operating Income
Forecast

48% / Year
Past Growth
35% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
48% / Year
Past Growth
35% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss

Over the last 2 years, the compound annual growth rate for Operating Income has been 48%. The projected CAGR for the next 2 years is 35%.

What are analyst estimates?

Pre-Tax Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
Pre-Tax Income Forecast
is not available for Life Science REIT PLC

Net Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
Net Income Forecast
is not available for Life Science REIT PLC

Continue LABS Research

Summary
LABS intrinsic value, competitors valuation, and company profile.
DCF Valuation
LABS stock valuation using Discount Cash Flow valuation method.
Relative Valuation
LABS stock valuation using valuation multiples.
Wall St Estimates
LABS price targets and financial estimates made by Wall Street analysts.
Profitability
Detailed analysis of the company's profitability.
Solvency
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
LABS stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall St Estimates
Profitability
Solvency
Financials
Discount Rate
Other Life Science REIT PLC listings:
F • EUR
JL6
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is LABS's stock price target?
Not Available

LABS does not have any price targets made by Wall Street professionals.

What is the Revenue forecast for Life Science REIT PLC?
Projected CAGR
19%

Over the last 2 years, the compound annual growth rate for Revenue has been 14%. The projected CAGR for the next 2 years is 19%.

What is the Operating Income forecast for Life Science REIT PLC?
Projected CAGR
35%

Over the last 2 years, the compound annual growth rate for Operating Income has been 48%. The projected CAGR for the next 2 years is 35%.

Back to Top
ALPHA SPREAD
Follow us
Join 351,400+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Valuation Backtest Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.

AI Assistant
Get AI-powered insights for any company or topic.
Open AI Assistant
Other Tools
Stock Screener
Discover stocks
Stock Comparison
Smarter decisions through side-by-side analysis
Intrinsic Value Calculator
Discover the true worth of your stocks
DCF Value Calculator
Harness the power of DCF

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett